Obesity medications, once facing shortages, are now widely available. So how do consumers not get scammed into purchasing ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Eli Lilly Canada is pleased to announce that ZEPBOUND™ KwikPen® (tirzepatide injection) is now available in Canada, providing a new, innovative treatment for adult Canadians living with obesity ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, others are continuing and pushing regulatory boundaries.

When buying Zepbound online, choosing the safest and most trustworthy providers is important. See our top picks.

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims.

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick with strong growth potential.

Eli Lilly Canada is pleased to announce that ZEPBOUND™ KwikPen® (tirzepatide injection) is now available in Canada, providing a new, innovative treatment for adult Canadians living with obesity or ...